olivLaw · US equity research
AirSculpt Technologies, Inc. AIRS
Services-Offices & Clinics of Doctors of Medicine · SIC 8011 · Vertical: Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
AirSculpt Technologies is a national provider of premium body contouring procedures that uses its patented AirSculpt® method to remove fat and tighten skin in a minimally invasive way. The company has had a difficult stretch, with revenue of 151.8 million USD in 2025, and is now trying to return to growth amid intense competition and pressure from weight-loss drugs.
At the close of 05 Nov 2026, AirSculpt Technologies, Inc. (AIRS) stock was 1.44 USD (−15.29% on the day), with market capitalisation 103.8 m USD, dividend yield 28.47%, beta 2.48, 52-week range 1.17–10.49 USD. Latest reported quarter (Q2 2026): revenue of 42.9 m USD (−2.5% YoY), net income of -1.1 m USD, diluted EPS -0.02 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 42.0
- weak (30–45)
- Bollinger (20, 2)
- 1.07 – 1.82
- in the lower half of the band · %B 0.49 · band width 51.8%
- SMA 50 / 200
- 1.91 / 3.10
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.10 / -0.17
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −22.6% | −5.9% | −16.6 pp | — |
| 3 months | −69.8% | −4.6% | −65.2 pp | — |
| 6 months | −58.4% | +0.2% | −58.6 pp | — |
| Year to date | −27.3% | +7.4% | −34.7 pp | — |
| 1 year | −85.0% | +8.2% | −93.2 pp | −4.4% |
| 3 years | −77.4% | +68.4% | −145.9 pp | −51.1% |
| 5 years | −90.0% | +56.5% | −146.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.5 m | 39.2 m | 39.4 m | 44.0 m | 35.0 m | 33.4 m | 39.4 m | 42.9 m |
| Cost of revenue | 17.8 m | 16.5 m | 16.0 m | 17.2 m | 14.9 m | 13.7 m | 15.6 m | 16.6 m |
| SG&A | 25.5 m | 23.4 m | 21.8 m | 22.7 m | 19.5 m | 18.2 m | 22.6 m | 23.4 m |
| Operating income | -3.7 m | -3.9 m | -1.6 m | 786.0 k | -9.8 m | -1.0 m | -1.8 m | -29.0 k |
| Depreciation & amortisation | 3.0 m | 3.2 m | 3.2 m | 3.2 m | 3.2 m | 3.1 m | 3.0 m | 2.9 m |
| Interest expense | 1.6 m | 1.6 m | 1.6 m | 1.6 m | 1.4 m | 1.5 m | 1.2 m | 1.0 m |
| Pre-tax income | -5.3 m | -5.5 m | -3.2 m | -776.0 k | -11.2 m | -2.5 m | -2.9 m | -1.2 m |
| Income tax | 733.0 k | -706.0 k | -367.0 k | -185.0 k | -1.6 m | -3.8 m | -465.0 k | -101.0 k |
| Net income | -6.0 m | -4.8 m | -2.8 m | -591.0 k | -9.5 m | 1.3 m | -2.4 m | -1.1 m |
| Diluted EPS | -0.10 | -0.08 ≈ | -0.05 | -0.01 | -0.15 | 0.02 ≈ | -0.03 | -0.02 |
| Operating cash flow | 1.8 m ≈ | 2.7 m | 868.0 k | 5.0 m ≈ | -225.0 k ≈ | -2.5 m | 5.3 m | -1.2 m ≈ |
| Capex | 4.9 m ≈ | 3.5 m | 1.9 m | 265.0 k ≈ | 180.0 k ≈ | 58.0 k | 51.0 k | 228.0 k ≈ |
| Dividends paid | 0 | 238.0 k | 0 | 0 | 0 | 0 | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 41.2 m | 62.8 m | 133.3 m | 168.8 m | 195.9 m | 180.4 m | 151.8 m |
| Revenue YoY | unavailable | +52.2% | +112.4% | +26.6% | +16.1% | −7.9% | −15.8% |
| Net income | -2.2 m | 7.6 m | 10.6 m | -14.7 m | -4.2 m | -8.0 m | -11.7 m |
| Net income YoY | unavailable | unavailable | +39.3% | −239.1% | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -0.01 | -0.26 | -0.08 | -0.14 | -0.19 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -5.4% | 12.1% | 7.9% | -8.7% | -2.2% | -4.4% | -7.7% |
| Free cash flow | 499.0 k | 10.3 m | 19.5 m | 11.5 m | 14.0 m | -2.7 m | 692.0 k |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 8.4 m USD
- Financial debt
- 56.0 m USD
- Net debt
- 47.6 m USD
- Equity
- 87.7 m USD
- Total assets
- 187.3 m USD
- Debt / equity
- 0.64x
- Current ratio
- 0.55x
- ROE
- -14.1%
- ROA
- -5.8%
- FCF margin
- 0.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 62.8 m | 133.3 m | 168.8 m | 195.9 m | 180.4 m | 151.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Cost of revenue | 23.5 m | 44.5 m | 62.8 m | 73.8 m | 71.1 m | 61.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Gross profit | 39.3 m ≈ | 88.8 m ≈ | 106.0 m ≈ | 122.1 m ≈ | 109.2 m ≈ | 90.1 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| SG&A | 23.6 m | 65.7 m | 101.4 m | 102.4 m | 98.9 m | 82.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Operating income | 10.0 m | 15.8 m | -4.5 m | 9.7 m | -1.6 m | -11.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Depreciation & amortisation | 5.6 m | 6.6 m | 8.1 m | 10.3 m | 11.9 m | 12.8 m | SEC (XBRL)· 31 Mar 2026verified |
| EBITDA | 15.7 m ≈ | 22.4 m ≈ | 3.5 m ≈ | 20.0 m ≈ | 10.3 m ≈ | 1.2 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Interest expense | 2.5 m | 4.9 m | 6.8 m | 6.5 m | 6.2 m | 6.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Pre-tax income | 7.6 m | 10.9 m | -11.3 m | 3.2 m | -7.8 m | -17.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Income tax | 0 | 329.0 k | 3.4 m | 7.5 m | 188.0 k | -6.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Net income | 7.6 m | 10.6 m | -14.7 m | -4.2 m | -8.0 m | -11.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Diluted EPS | — | -0.01 | -0.26 | -0.08 | -0.14 | -0.19 | SEC (XBRL)· 31 Mar 2026verified |
| Weighted average diluted shares | — | 55.6 m | 55.7 m | 56.8 m | 57.7 m | 60.5 m | SEC (XBRL)· 31 Mar 2026verified |
| Dividend per share | — | — | 0.41 | — | — | — | SEC (XBRL)· 14 Mar 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 10.4 m | 25.3 m | 9.6 m | 10.3 m | 8.2 m | 8.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Current assets | 11.6 m | 29.4 m | 16.7 m | 16.0 m | 17.1 m | 15.5 m | SEC (XBRL)· 31 Mar 2026verified |
| Property, plant & equipment, net | 7.1 m | 13.6 m | 24.2 m | 28.9 m | 37.5 m | 27.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Goodwill | 81.7 m | 81.7 m | 81.7 m | 81.7 m | 81.7 m | 81.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Intangibles (excl. goodwill) | 60.6 m | 55.9 m | 51.1 m | 46.3 m | 41.6 m | 36.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Total assets | 179.6 m | 200.6 m | 200.8 m | 204.0 m | 212.8 m | 187.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Accounts payable | 1.1 m | 2.7 m | 3.8 m | 3.9 m | 6.3 m | 5.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Short-term debt | 400.0 k | 850.0 k | 2.1 m | 2.1 m | 4.3 m | 5.5 m | SEC (XBRL)· 31 Mar 2026verified |
| Long-term debt | 32.1 m | 81.8 m | 81.4 m | 69.5 m | 65.5 m | 50.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Current liabilities | 9.5 m | 16.4 m | 22.3 m | 20.3 m | 28.9 m | 27.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Total liabilities | 55.9 m | 117.0 m | 130.0 m | 120.0 m | 134.6 m | 99.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Equity | — | 83.5 m † | 70.8 m † | 82.7 m † | 78.2 m † | 87.7 m † | SEC (XBRL)· 31 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 14.0 m | 26.6 m | 24.4 m | 24.0 m | 11.4 m | 3.1 m | SEC (XBRL)· 31 Mar 2026verified |
| Capex | 3.7 m | 7.1 m | 12.9 m | 9.9 m | 14.0 m | 2.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Free cash flow | 10.3 m ≈ | 19.5 m ≈ | 11.5 m ≈ | 14.0 m ≈ | -2.7 m ≈ | 692.0 k ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Investing cash flow | -3.7 m | -7.1 m | -12.9 m | -9.9 m | -14.0 m | -2.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Financing cash flow | -5.0 m | -4.5 m | -27.3 m | -13.4 m | 630.0 k | -478.0 k | SEC (XBRL)· 31 Mar 2026verified |
| Dividends paid | 0 | 0 | 23.2 m | 385.0 k | 252.0 k | 0 | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 54.2% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 103.8 m USD
Key indicators
Coverage and freshness
Score by group
54% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.56 – 7.25 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)0.56 – 1.18 (Mid 0.79)WACC 8.0% · starting FCFF 5.1 m USD · terminal value share of EV 76%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): 16.8%
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)5.39 – 7.25 (Mid 6.18)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 54.2% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -7.9% | 0 (on a fixed band) | 19% |
| Net margin · Quality | -7.8% | 25 (vs peers) | 12% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -3.5% | 0 (on a fixed band) | 15% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -2.5x | 0 (on a fixed band) | 12% |
| Current ratio · Balance sheet | 0.8x | 0 (on a fixed band) | 8% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 0.7% | 9 (on a fixed band) | 15% |
| Shareholder yield (distributions) · Returns | 0.0% | 0 (on a fixed band) | 12% |
| Payout ratio (FCF) · Returns | 0.0% | 100 (on a fixed band) | 8% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet0/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality9/100 · 2/3 factors with a value
- Returns40/100 · 2/2 factors with a value
- Valuation· partial9/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
AirSculpt Technologies, Inc. (AIRS). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 151.8 m USD in 2025; YoY growth -15.8%; net margin -7.8%; ROE -12.0%.
The estimated value range is 2.98–4.21 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 3.48 USD, the price of 1.44 USD leaves a potential of 141.9% (value / price − 1) and a margin of safety of 58.7% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 54.2% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Payout ratio (FCF): 0.0%
- The price is below the estimated value range
What contradicts it
- ROIC: -7.9%
- Net margin: -7.8%
- Revenue CAGR 3Y: -3.5%
- Interest coverage: -2.5x
- Current ratio: 0.8x
- FCF yield: 0.7%
- Shareholder yield (distributions): 0.0%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA.
Versus the vertical median
Services-Offices & Clinics of Doctors of Medicine (SIC 8011) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TDOCTeladoc Health, Inc. | 1.7 bn | — | -11.5% | -6.3% | −1.5% | +24% / −48% |
| STLNStarling Oncology, Inc. | 682.8 m | — | — | -6.2% | +27.8% | +113% / +292% |
| SBCSBC Medical Group Holdings Incorporated | 516.3 m | 10.7 | 19.3% | 28.0% | −15.5% | +41% / −54% |
| CCMConcord Medical Services Holdings Ltd | 463.7 m | — | — | -20.2% | +25.2% | −8% / −65% |
| LFMDLifeMD, Inc. | 110.4 m | — | 6.5% | 0.1% | +25.3% | −40% / −70% |
| AIRSAirSculpt Technologies, Inc. | 103.8 m | — | -12.0% | -7.8% | −15.8% | −85% / −77% |
| BMGLBasel Medical Group Ltd | 8.2 m | — | -169.7% | -94.0% | unavailable | −64% / unavailable |
| HIMSHims & Hers Health, Inc. | 0 | — | -32.0% | -5.5% | +59.0% | −39% / +171% |
| AUNAAuna S.A. | — | — | 7.5% | 2.5% | +13.2% | −1% / unavailable |
1- and 3-year price returns: for AIRS from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
AirSculpt Technologies is a national provider of premium body contouring procedures that uses its patented AirSculpt® method to remove fat and tighten skin in a minimally invasive way. The company has had a difficult stretch, with revenue of 151.8 million USD in 2025, and is now trying to return to growth amid intense competition and pressure from weight-loss drugs.
SWOT
Strengths
- The AirSculpt® brand has recognition and a patented method, which the company protects through exclusive availability at its own centers.
- The full upfront payment model removes reimbursement risk and supports attractive unit economics at the center level.
- The company has a broad portfolio of procedures, including fat transfer and skin tightening treatments, which diversifies the offering.
Weaknesses
- Revenue declined in 2024 and 2025, and case volume at comparable centers fell significantly.
- The company posted net losses in 2025 and in the first six months of 2026, and debt and liquidity remain a concern.
- The company depends on a single third-party manufacturer for key elements of the tools used in its procedures.
Opportunities
- If the new services, including the AlloClae partnership, expand the eligible patient population, the company could resume growth.
- The addressable market, which the company describes as growing, could support expansion if demand returns.
- Optimizing marketing spend and expanding consumer financing options could improve patient conversion.
Threats
- Weight-loss drugs could reduce demand for fat reduction procedures, and their long-term effect is hard to predict.
- Competitors could develop methods that are safer or easier to adopt, which could reduce the value of the brand.
- Legal risks, medical malpractice claims and regulation of medical practice could affect the company's operating model.
Risks
- Continued revenue declinehigh
Revenue fell in 2024 and 2025, and recovery depends on the success of growth strategies. The company acknowledges that it could see short-term declines while implementing them.
- Debt and liquidityhigh
The company has reduced its debt but still has payment obligations to meet, and loan conditions limit financial flexibility.
- Dilution from share issuancesmedium
Share issuances under the at-the-market program could dilute existing shareholders, and loan terms require part of the proceeds to repay debt.
- Response to weight-loss drugsmedium
If demand for fat reduction procedures falls because of these drugs, the company's revenue could be affected over the long term.
- Regulation and medical liabilitymedium
Changes to laws on medical practice and malpractice liability could force a restructuring of relationships with the surgeons' professional associations.
Investment thesis
What would need to be true (bull case)
- If the recovery in case volume at comparable centers takes hold and the new services attract new patients, the company could gradually return to growth with attractive unit economics.
- Continued debt reduction and higher cash could be a positive sign, lowering liquidity risks.
- If the addressable market grows as the company's study estimates, the brand and patented method could hold a long-term advantage.
What would break the thesis
- If the decline in demand continues and revenue keeps falling, the company could struggle to meet its 2026 guidance.
- Debt, net losses and the need for equity capital could limit the company's flexibility and dilute shareholders.
- Weight-loss drugs and non-surgical competition could reduce procedure demand and erode the brand's advantage.
What to watch
- Case volume at comparable centers and third-quarter revenueQ3 2026
- Delivery against the 2026 revenue and adjusted EBITDA guidance2026
- Early results of the AlloClae partnership and new servicesnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
AirSculpt offers body contouring procedures through its own centers, with a premium model and a central patented method, AirSculpt®, which removes fat and tightens skin without needles, scalpels or general anesthesia. Its services include fat transfer (Power BBL®, Up a Cup™, Hip Flip™) and treatments for skin tightening and cellulite reduction. Each center works through a professional association of surgeons, and the company operates as a holding company through management service agreements. Clients pay fully upfront with no reimbursement risk, and across 31 centers in 20 U.S. states and Canada the company performed 11,852 procedures in 2025.
The business model relies on a relatively small number of centers with attractive unit economics, which the company says can become profitable in about three months. Revenue per case was 12,809 USD in 2025, roughly flat from the prior year, while the number of cases fell sharply. The company argues it can improve margins through optimized marketing, better sales execution, consumer financing and new product lines.
In 2026 the company introduced new services, including an exclusive partnership with AlloClae for an injectable adipose matrix, and reduced gross debt, which stood at 44.2 million USD on June 30, 2026. The near-term strategy is to stabilize revenue and protect liquidity rather than open new centers.
Segments
Body contouring procedures (AirSculpt® method)
The patented AirSculpt® method is the core of the offering and is available only at the company's centers. The procedure removes fat and tightens skin in a single session with quick recovery, and the company says the method has advantages over conventional liposuction.
Fat transfer and enhancement procedures
Power BBL®, Up a Cup™ and Hip Flip™ use the patient's own fat to reshape the buttocks, breasts or hips, without silicone implants. These procedures are an important revenue and innovation driver, and the company keeps developing them.
Skin tightening and cellulite reduction treatments
AirSculpt® + combines the core method with skin tightening, while AirSculpt® Smooth targets cellulite on the buttocks and thighs. The company has indicated that extending these services as standalone products is part of its 2026 growth strategy.
Market context
The market environment has weighed on the company in 2025 and 2026, and the decline in case volume at comparable centers points to weaker demand than expected in the aesthetics sector. If demand stabilizes, the company could gradually recover volumes, though this is not certain.
Trends
- Rising popularity of weight-loss drugsmixed
GLP-1 medications could reduce demand for fat reduction procedures, but they may also increase interest in body contouring and skin tightening after weight loss. The net effect remains uncertain, and the company acknowledges it cannot predict the impact.
- Growing self-image awareness and social acceptancetailwind
Social media and reduced stigma are making aesthetic procedures more accepted, and the company benefits from digital campaigns and before-and-after content. This is a favorable long-term trend.
- More cautious consumersheadwind
Lower consumer confidence and disposable income could reduce demand for costly procedures paid fully out of pocket, and the company has no reimbursement to cushion the effect.
- Advances in minimally invasive technologymixed
Faster recovery and less invasive technologies are an advantage for the company, but they also let competitors copy or develop similar methods.
Competitive position
Competition comes from liposuction, abdominoplasty and non-surgical fat reduction treatments using cooling, injections or ultrasound. The company argues that alternatives offer less predictable results, but competitors could develop methods that are safer or easier to use, which could reduce the company's commercial opportunities.
Competition for qualified surgeons is intense, and the company offers attractive part-time compensation to attract them. Brand protection, however, depends on AirSculpt® being available only at the company's own centers.
- Traditional plastic surgery (liposuction and abdominoplasty)
Conventional surgical procedures are the main alternative for patients seeking fat reduction, and the company describes them as more invasive.
- Non-surgical fat reduction treatments
Cooling, ultrasound and laser treatments are non-surgical options that compete for the same patient spending.
- Weight-loss medications
The source describes these drugs as an alternative that could reduce demand for fat reduction procedures.
- Other body contouring providers and aesthetic clinics
The company operates in a fragmented market where local clinics and providers compete for the same patients.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Live updates: GOP airs frustration over Russia sanctions waiver; Trump heads to KansasThe Hill · 19 Oct 2026 · EN
- Iranian TV airs video said to show tanker explosion in HormuzAl Jazeera English · 17 Oct 2026 · EN
- 🇸🇦 ❌ 🇾🇪 🇾🇪 — Yemen’s National Army (YNA) has released footage showing Saudi airs…Telegram — Intel Slava Z (pro-RU OSINT EN) · 14 Oct 2026 · EN
- Govt airs new ad after Trump says MAGA Inc. PAC will pay for controversial TV spotsCNBC — Top News · 06 Oct 2026 · EN
- White House airs taxpayer-funded ad talking about ‘the final battle’The Hill · 28 Sept 2026 · EN
- House ‘member day’ hearing airs reform proposalsThe Hill · 10 Sept 2026 · EN
- Siberian Communist Party candidate for Russia’s State Duma airs TV campaign ad with slogan ‘Peace to the world’Meduza English (independent RU/exile) · 31 Aug 2026 · EN
SEC filings
- Current report12 Aug 2026Other events · Financial statements and exhibits
- Quarterly report10 Aug 2026
- Current report10 Aug 2026Results of operations · Financial statements and exhibits
- Current report14 May 2026Shareholder vote
- Quarterly report08 May 2026
- Current report08 May 2026Results of operations · Financial statements and exhibits
- Proxy statement15 Apr 2026
- Current report (amendment)06 Apr 2026Results of operations · Financial statements and exhibits
- Current report02 Apr 2026Results of operations · Financial statements and exhibits
- Annual report31 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / AirSculpt Technologies, Inc. · 31 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / AirSculpt Technologies, Inc. · 10 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / AirSculpt Technologies, Inc. · 10 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.